GRAPPA members’ responses to inclusion of a PsA measure in the CAPP.
| Total Respondents per Profession * | ||||||||
|---|---|---|---|---|---|---|---|---|
| Question | Response | Rheumatologist, n (%) 62 (58) | Dermatologist, n (%) 23 (22) | Other Clinical Roles, n (%) 6 (6) | Non-clinician Scientist, n (%) 3 (3) | Industry Professional, n (%) 21 (20) | Other, n (%) 1 (1) | Total, n (%) † |
| 1. Should CAPP include a PsA measure? | ||||||||
| Yes | 43 (69) | 13 (57) | 6 (100) | 3 (100) | 17 (81) | 1 (100) | 78 (74) | |
| No | 19 (31) | 10 (43) | 0 | 0 | 4 (19) | 0 | 28 (26) | |
| 2. Should the measure address PsA (present/absent) or measure PsA severity? | ||||||||
| PsA present/absent | 28 (45) | 5 (22) | 4 (67) | 1 (33) | 10 (48) | 0 | 45 (42) | |
| PsA severity | 15 (24) | 9 (39) | 2 (33) | 2 (67) | 5 (24) | 1 (100) | 32 (30) | |
| Both | 5 (8) | 1 (4) | 0 | 0 | 3 (14) | 0 | 8 (8) | |
| Neither | 14 (23) | 8 (35) | 0 | 0 | 3 (14) | 0 | 21 (20) | |
| 3. How should PsA be measured?‡ | ||||||||
| Peripheral | 6 (10) | 0 | 0 | 1 (33) | 5 (24) | 0 | 11 (10) | |
| Axial | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Both | 41 (66) | 15 (65) | 6 (100) | 2 (67) | 12 (57) | 1 (100) | 71 (68) | |
| Neither | 15 (24) | 8 (35) | 0 | 0 | 3 (14) | 0 | 23 (22)* | |
Respondents claiming multiple professional categories are annotated in all applicable categories.
↵† Respondents claiming multiple professional categories are annotated as a single response.
↵‡ One response (“peripheral” and “neither”) was omitted. GRAPPA: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; CAPP: Comprehensive Assessment of the Psoriasis Patient; PsA: psoriatic arthritis.